Dovato is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.¹
Learn more about Dovato below
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: January 2022 PM-IE-DLL-WCNT-200015